Theravance Biopharma, Inc. (NASDAQ:TBPH) Short Interest Down 14.5% in April

Theravance Biopharma, Inc. (NASDAQ:TBPH) saw a large drop in short interest in the month of April. As of April 15th, there was short interest totalling 6,430,000 shares, a drop of 14.5% from the March 31st total of 7,520,000 shares. Currently, 14.7% of the shares of the stock are sold short. Based on an average daily volume of 367,200 shares, the days-to-cover ratio is currently 17.5 days.

Theravance Biopharma Stock Down 0.2 %

Shares of Theravance Biopharma stock opened at $9.12 on Monday. The stock’s fifty day moving average is $9.08 and its 200-day moving average is $9.68. The firm has a market capitalization of $442.87 million, a PE ratio of -9.40 and a beta of 0.36. Theravance Biopharma has a 12-month low of $8.21 and a 12-month high of $11.98.

Theravance Biopharma (NASDAQ:TBPH) last announced its earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). The company had revenue of $17.57 million for the quarter, compared to analyst estimates of $17.49 million. Theravance Biopharma had a negative return on equity of 19.31% and a negative net margin of 96.12%. Analysts expect that Theravance Biopharma will post -0.84 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on TBPH. BTIG Research began coverage on Theravance Biopharma in a research report on Friday, April 12th. They set a “buy” rating and a $21.00 target price on the stock. Evercore ISI lowered Theravance Biopharma from an “outperform” rating to an “inline” rating in a research report on Monday, January 8th.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of TBPH. China Universal Asset Management Co. Ltd. raised its position in Theravance Biopharma by 324.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,759 shares of the biopharmaceutical company’s stock valued at $65,000 after buying an additional 4,402 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Theravance Biopharma by 31.4% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,330 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 2,227 shares in the last quarter. Gerber LLC purchased a new position in Theravance Biopharma in the fourth quarter valued at about $112,000. Simplicity Solutions LLC purchased a new position in Theravance Biopharma in the fourth quarter valued at about $141,000. Finally, Bleakley Financial Group LLC purchased a new position in Theravance Biopharma in the fourth quarter valued at about $141,000. 99.10% of the stock is owned by institutional investors and hedge funds.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.